Home » Topics » BioWorld Science, Cardiovascular

BioWorld Science, Cardiovascular
RSS

Tanabe Seiyaku investigates ET antagonists

April 26, 1996

ACE/NEP inhibitors claimed by Fujisawa

April 26, 1996

BMS's ACE/NEP inhibitors in phase I

April 26, 1996

Yamanouchi selects YM-471 for clinical development

April 19, 1996

Corvert now available in U.S.

April 19, 1996

Posicor submitted for approval

April 19, 1996

New ETA antagonist from SmithKline Beecham: SB-225757

April 19, 1996

EMD-94246, promising endothelin antagonist for hypertension

April 19, 1996

Zanidip approved for marketing in U.K.

April 19, 1996

CP-191166, angiotensin II antagonist from Pfizer

April 19, 1996

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for May 6, 2026.
News in brief
BioWorld Asia
BioWorld Asia briefs for May 5, 2026
Cytospire raises £61M series A to target EGFR in solid tumors
BioWorld
Next-generation T-cell engager (TCE) specialist Cytospire Therapeutics Ltd. has raised £61 million (US$82.7 million) in a series A round, equipping it to advance...
Bio Korea 2026: US policy risks shift to execution framework
BioWorld
Regulatory uncertainty that dominated the life science sector in 2025 is transitioning into an execution framework for biotechnology companies, provided companies...
Latus Bio series A financing supports early-stage programs
BioWorld Science
Latus Bio Inc. has closed a $97 million series A financing to support its broad therapeutics pipeline based on novel AAV capsid variants. Proceeds from the...